Monday, January 5, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback